论文部分内容阅读
作者对162名年龄在18～40岁、血清甲型肝炎病毒（HAV）抗体阴性的健康志愿者进行了临床试验。 由SmithKline公司提供甲型肝炎灭活疫苗,单剂接种剂量为1440ELISA单位/ml,用Abbort HAVAB试剂盒进行血清学检测。以世界卫生组织提供的标准抗HAV免疫球蛋白作系列稀释进行抗体滴度定量。 检测结果表明,免疫14天后,145人血清阳转,阳转率为96％（145/151）,几何平均滴度（GMT）为 155mIU/ml（11～1800mIU/ml）,血清仍呈阴性的6人抗体滴度为11～
The authors conducted a clinical trial of 162 healthy volunteers aged 18-40 years with negative serum hepatitis A virus (HAV) antibodies. Hepatitis A inactivated vaccine was provided by SmithKline with a single dose of 1440 ELISA units / ml and serological testing with the Abbort HAVAB kit. Antibody titers were quantified using serial dilutions of standard anti-HAV immunoglobulins provided by the World Health Organization. The results showed that after 14 days of immunization, 145 were seroconverted and the positive rate was 96% (145/151). The geometric mean titer (GMT) was 155mIU / ml (11-1800mIU / ml) and the serum was still negative 6 human antibody titer of 11 ~